Search results
Q&A: This New CEO Has Big Ideas For A Small Biotech
Investor's Business Daily· 7 hours agoCatalyst Pharmaceuticals' (CPRX) new Chief Executive, Richard Daly, is no stranger to working at big companies. Catalyst is not a pharma giant. Former...
Jazz Pharma to Fight FDA in Court Over Rival Sleep Drug Approval
Bloomberg Law· 1 day agoA pharmaceutical manufacturer known for its sleep medicines will argue Friday before a federal district court that the FDA violated an orphan drug law when ...
These congressmen want to modify the Inflation Reduction Act to foster rare disease research
The Hill· 22 hours agoReps. John Joyce (R-Pa.) and Wiley Nickel (D-N.C.) discussed Thursday why they’re pushing to pass...
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
GuruFocus.com via Yahoo Finance· 3 hours agoOperational and Strategic Developments Arcellx continues to make significant strides in its clinical developments. The company's lead product candidate, anito-cel, has received Fast Track, & ...
How to find more information about a drug that your doctor prescribed
Medical Xpress· 5 hours agoYou'd also like to know things such as how quickly the drug was approved by Health Canada, whether...
Shionogi secures licence for Maze’s Pompe disease treatment
Pharmaceutical Technology via Yahoo Finance· 10 hours agoIts potential extends to both a standalone treatment and an adjunctive therapy alongside enzyme...
SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer
WPRI Providence· 16 hours agoSN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer ...
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare...
San Mateo Daily Journal· 1 day agoJaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS
STEALTH BIOTHERAPEUTICS' BARTH SYNDROME NDA RECEIVES PRIORITY REVIEW DESIGNATION
KOIN News 6 Portland· 3 days agoStealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for diseases involving mitochondrial dysfunction ...
Lisata Therapeutics reports strong 1Q performance, cash to support operations into 2026
Proactive Investors· 1 day agoCEO David Mazzo told shareholders that the company is off to a strong start to 2024, with Phase 2b...